Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 50

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016', provides in depth analysis on Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted pipeline therapeutics.

The report provides comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)

- The report reviews Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics and enlists all their major and minor projects

- The report assesses Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) Overview 6
Therapeutics Development 7
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Products under Development by Stage of Development 7
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Products under Development by Therapy Area 8
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Products under Development by Indication 9
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Products under Development by Companies 12
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Products under Development by Universities/Institutes 14
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Companies Involved in Therapeutics Development 21
Conatus Pharmaceuticals Inc. 21
LG Life Science LTD. 22
New World Laboratories, Inc. 23
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Drug Profiles 24
ED-11 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
emricasan - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
nivocasan - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
NWL-154 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Dormant Projects 34
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Featured News & Press Releases 36
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial 36
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data 37
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting 38
Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis 38
Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis 38
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 39
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting 41
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 41
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 42
Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting 42
Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis 43
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement 44
Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 45
Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 47
Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Conatus Pharmaceuticals Inc., H2 2016 21
Pipeline by LG Life Science LTD., H2 2016 22
Pipeline by New World Laboratories, Inc., H2 2016 23
Dormant Projects, H2 2016 34
Dormant Projects (Contd..1), H2 2016 35

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 9
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 19
  • United States Industrial Enzymes Market Report 2016
    Published: 02-Dec-2016        Price: US 3800 Onwards        Pages: 108
    Notes: Sales, means the sales volume of Industrial Enzymes Revenue, means the sales value of Industrial Enzymes This report studies sales (consumption) of Industrial Enzymes in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Novozymes - Dupont - DSM - BASF - AB Enzymes - CHR.Hansen - Amano Enzyme Inc. - Soufflet Group - Dyadic Inter......
  • Global Pectinase Sales Market Report 2020
    Published: 01-Dec-2016        Price: US 4000 Onwards        Pages: 125
    This report studies sales (consumption) of Pectinase in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Novozymes - Genencor (DuPont) - Amano Enzyme - DSM - AB Enzymes - Verenium (BASF) - Shandong Longda - YSSH - Jinyuan - Sunson - Saide......
  • China DNA Polymerase Market Research Report 2016
    Published: 01-Dec-2016        Price: US 3200 Onwards        Pages: 122
    Notes: Sales, means the sales volume of DNA Polymerase Revenue, means the sales value of DNA Polymerase This report studies DNA Polymerase in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Thermo Fisher Scientific Inc. - GenScript - QIAGEN - Sigma-Aldrich Co. LLC. - Genomic Vision - Aidab Biotechnologies - Beijing Su......
  • Global Superoxide dismutase (SOD) Market Research Report 2016
    Published: 29-Nov-2016        Price: US 2900 Onwards        Pages: 101
    Notes: Production, means the output of Superoxide Dismutase (SOD) Revenue, means the sales value of Superoxide Dismutase (SOD) This report studies Superoxide Dismutase (SOD) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Bionov - Worthington Biochemical Corporation......
  • Global Collagenase Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 28-Nov-2016        Price: US 3480 Onwards        Pages: 110
    Collagenase, obtained from Clostridium histolyticum, is an enzyme used for tissue dissociation in vitro and thus for isolation of many different types of cells. These isolated cells are then used for numerous clinical and research applications.Scope of the Report:This report focuses on the Collagenase in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regi......
  • United States Lipase Market Report 2016
    Published: 28-Nov-2016        Price: US 3800 Onwards        Pages: 110
    Notes: Sales, means the sales volume of Lipase Revenue, means the sales value of Lipase This report studies sales (consumption) of Lipase in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Advanced Enzymes - Amano Enzymes Inc. - Associated British Foods Plc - Chr. Hansen Holdings A/S - Clerici-Sacco Group - E. I. Du Pont De Nemours and Company (Genencor......
  • Alpha Glucosidase Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Alpha Glucosidase Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Alpha Glucosidase Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, c......
  • GABA Transaminase Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "GABA Transaminase Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the GABA Transaminase Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, c......
  • Plasminogen Activators -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Plasminogen Activators-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Plasminogen Activators. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaboration......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs